Lilly Wong is Vice President, Clinical Translation at Fate Therapeutics, where she oversees the development and implementation of translational strategies for clinical programs in hematology-oncology, solid tumors, and autoimmune diseases. With over 20 years of experience in translational research, Dr. Wong has expertise in biomarker discovery, clinical assay development, pharmacokinetics/pharmacodynamics (PK/PD), patient enrichment hypotheses, and combination strategies. Before joining Fate, Dr. Wong served as Director of Translational Medicine at Bristol Myers Squibb, where she led clinical biomarker development and combination strategies for a novel CELMoD in relapsed/refractory multiple myeloma. She also held several scientific and leadership roles at Celgene Corporation. Dr. Wong earned both her Ph.D. and B.S. in Chemistry and Biochemistry from the University of California, San Diego.
